Key Highlights

Risk & Performance

Pipeline Risk Assessment

Pipeline Risk Assessment

Based on historical performance

Moderate Risk

Score: 45/100

Failure Rate

0.0%

0 terminated/withdrawn out of 8 trials

Success Rate

100.0%

+13.5% vs industry average

Late-Stage Pipeline

13%

1 trials in Phase 3/4

Results Transparency

0%

0 of 4 completed trials have results

Key Signals

Enrollment Performance

Analytics

Phase 1
5(62.5%)
Phase 2
2(25.0%)
Phase 3
1(12.5%)
8Total
Phase 1(5)
Phase 2(2)
Phase 3(1)

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (8)

Showing 8 of 8 trials
NCT07466940Phase 1Active Not Recruiting

A Clinical Study to Evaluate SM17 in Healthy Participants

Role: lead

NCT07445919Phase 2Not Yet Recruiting

A Clinical Study to Evaluate SM17 for Atopic Dermatitis

Role: lead

NCT07103369Phase 1Completed

A Phase I Clinical Study to Evaluate SM17 in Chinese Healthy Subjects and Patients With Moderate to Severe Atopic Dermatitis

Role: lead

NCT05332834Phase 1Completed

A Phase 1 Study of Single and Multiple Intravenous Doses of SM17 in Healthy Subjects

Role: lead

NCT04704492Phase 1Completed

A Study of the Pharmacokinetics and Safety of SM03 in Patients With Rheumatoid Arthritis

Role: lead

NCT04312815Phase 3Unknown

A Study Assessing the Efficacy and Safety of SM03 in Patients With Active Rheumatoid Arthritis Receiving MTX

Role: lead

NCT04192617Phase 2Completed

A Study to Evaluate the Safety and Efficacy of SM03 in Patients With Rheumatoid Arthritis Receiving Methotrexate

Role: lead

NCT04041544Phase 1Unknown

A Study to Evaluate Safety, Tolerability, Pharmacokinetics and Pharmacodynamics in Health Subject

Role: lead

All 8 trials loaded